WO2009112874A1 - Modified release composition comprising doxofylline - Google Patents

Modified release composition comprising doxofylline Download PDF

Info

Publication number
WO2009112874A1
WO2009112874A1 PCT/IB2008/000554 IB2008000554W WO2009112874A1 WO 2009112874 A1 WO2009112874 A1 WO 2009112874A1 IB 2008000554 W IB2008000554 W IB 2008000554W WO 2009112874 A1 WO2009112874 A1 WO 2009112874A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
cellulose
doxofylline
polymer
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2008/000554
Other languages
French (fr)
Inventor
Frederick Van Gulik
Rao Yamsani Madhusudan
Gannu Ramesh
Bandari Suresh
Prabha Shakar Bodapunti
Original Assignee
Eurodrug Laboratories B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurodrug Laboratories B.V. filed Critical Eurodrug Laboratories B.V.
Priority to MX2008010233A priority Critical patent/MX2008010233A/en
Priority to PCT/IB2008/000554 priority patent/WO2009112874A1/en
Priority to KR1020087020018A priority patent/KR101697773B1/en
Priority to IT000798A priority patent/ITMI20080798A1/en
Priority to EP09721101A priority patent/EP2262485A1/en
Priority to PCT/EP2009/052675 priority patent/WO2009112436A1/en
Priority to AU2009224801A priority patent/AU2009224801B2/en
Priority to BRPI0906158A priority patent/BRPI0906158B8/en
Priority to MX2010009917A priority patent/MX2010009917A/en
Publication of WO2009112874A1 publication Critical patent/WO2009112874A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Definitions

  • the present invention concerns a new doxofylline comprising pharmaceutical composition, in particular a modified release formulation, for administration once a day only.
  • Doxofylline (7-(l,3-dioxalan-2-ylmethyl)-theophylline) is a drug derived from theophylline which is used in therapy as a bronchodilator, with anti-inflammatory action, in reversible airway obstruction. It is commonly administered in doses ranging from 800 to 1200 mg per day, orally, according to a dosage which provides for the intake of two to three dosage units per day in order to maintain therapeutically effective haematic levels.
  • the doxofylline tablets commercially available generally contain 400 mg of active ingredient and release almost all the drug within one hour from intake. The half-life of the drug is around 6-7 hours and for this reason several administrations are required during the 24-hour period.
  • compositions that can be administered once a day, bioequivalent to the plasmatic concentration obtained with the traditional compositions currently on sale, hi fact currently, dosage units containing 400 mg of active ingredient are currently administered two/three times a day for an average of approximately 1000 mg of active ingredient, a dosage considered necessary to maintain the therapeutic haematic levels of doxofylline.
  • One object of the present invention is to provide a modified release composition of doxofylline which is bioequivalent to the therapy currently used and which eliminates the need to take several doses per day, thus improving patient compliance.
  • a further object of the present invention is to provide a composition of doxofylline which eliminates the initial haematic peak and the first-pass effect occurring in the conventional compositions.
  • a further object of the present invention is to provide a doxofylline composition which maintains the effective concentration of the drug in the blood sufficient to exert the bronchodilatory and anti-inflammatory effect over the 24-hour period, thus reducing the risk of bronchospasm and serious consequences for the patient.
  • Another object of the present invention is to provide a modified release doxofylline composition which avoids the need for recourse to emergency drugs, such as salbutamol, to overcome acute asthmatic attacks and bronchospasms.
  • the invention concerns a modified release pharmaceutical composition which comprises as active ingredient doxofylline, and a polymer selected from a pharmaceutically acceptable cellulose derivative, a pharmaceutically acceptable methacrylate derivative, their mixtures, and pharmaceutically acceptable salts thereof.
  • Doxofylline or doxophylline
  • modified release pharmaceutical composition indicates a pharmaceutical composition that retains the active ingredient for a longer period of time than the conventional compositions and releases it slowly in order to maintain at length the plasmatic concentrations of the drug sufficient to exert the desired therapeutic effect.
  • Said formulation is here also called “BET” (Bioavailability Enhancing Technology) formulation.
  • polymer indicates, according to the present invention, a pharmaceutically acceptable release modulator polymer or copolymer, suitable for prolonging the release time of the active ingredient from the composition. Said polymer will be indicated below also simply as “release modulator polymer”.
  • pharmaceutically acceptable cellulose derivative indicates a derivative suitable for prolonging the release time of the drug from the composition, such as pharmaceutically acceptable cellulose esters and ethers, like methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, their mixtures and their salts.
  • pharmaceutically acceptable cellulose esters and ethers like methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, their mixtures and their salts.
  • pharmaceutically acceptable methacrylate derivative indicates a derivative suitable for prolonging the release time of the drug from the composition, for example the copolymer methacrylic acid/methyl methacrylate, the copolymer methacrylic acid/ethyl methacrylate, their mixtures and their salts.
  • a preferred release modulator polymer according to the invention is a pharmaceutically acceptable cellulose derivative, advantageously selected from methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose and their mixtures.
  • composition of the invention is preferably a composition in the form of a dosage unit suitable for oral administration once a day, advantageously in the form of a tablet.
  • composition of the invention preferably also comprises excipients useful for the processing thereof, for example lubricating agents, such as magnesium stearate, filling agents, such as lactose, talc, microcrystalline cellulose, agents aiding compression and, if necessary or desired, other excipients such as aromatizers, sweeteners, preservatives, etc., well known to a person skilled in the art.
  • excipients useful for the processing thereof for example lubricating agents, such as magnesium stearate, filling agents, such as lactose, talc, microcrystalline cellulose, agents aiding compression and, if necessary or desired, other excipients such as aromatizers, sweeteners, preservatives, etc., well known to a person skilled in the art.
  • the composition of the invention preferably comprises a quantity of active ingredient between 600 and 800 mg, preferably between 625 and 700 mg, advantageously around 650 mg. It is understood that said dose can vary according to the age, weight and state of health of the patient. It has been unexpectedly observed, however, during the bioequivalence assays, that it is not necessary to administer a quantity of active ingredient equal to the daily dosage of the conventional compositions currently on the market (400 mg, two/three times a day, on average 1,000 mg per day) but that thanks to the composition of the invention, it is possible to obtain a bioequivalent plasmatic concentration even at a very low dosage, for example with 650 mg of active ingredient.
  • the invention concerns a modified release composition which comprises as active ingredient approximately 650 mg of doxofylline and a release modulator polymer as defined above, advantageously in combination with a filling agent and/or a lubricant.
  • the release modulator polymers are used alone or mixed together, in quantities between 30 mg and 200 mg per tablet, preferably between 40 mg and 130 mg, for example, 50, 100 or 125 mg, per dosage unit.
  • composition of the invention has proved to be particularly suitable for modified release of the active ingredient and with one single oral administration allows an effective haematic concentration of doxofylline to be maintained for 24 hours, while time avoiding the excessive haematic peak which characterises the conventional compositions currently on sale.
  • the preferred composition of the invention advantageously also comprises a lubricant, for example magnesium stearate, for example in quantities between 1 and 15 mg, preferably between 3 and 10 mg, for example approximately 5 mg, per dosage unit.
  • the preferred composition of the invention advantageously also comprises one or more filling agents, such as talc, lactose or microcrystalline cellulose, for example in total quantities of between 10 and 200 mg, for example between 20 and 150 mg, advantageously 30, 50, 70 or 100 mg, per dosage unit.
  • filling agents such as talc, lactose or microcrystalline cellulose
  • composition of the invention is preferably in the form of a tablet and can be prepared by mixing the active ingredient, the release modulator polymer (or the mixture of polymers) and any other components and compressing them to an appropriate hardness, according to the methods known in the art.
  • the invention concerns use of the composition of the invention for the preparation of a bronchodilatory medication with anti- inflammatory action for the treatment of all forms of asthma and chronic obstructive pulmonary disease (COPD).
  • the invention concerns use of the composition of the invention for the preparation of a medication for oral adrninistration once a day only.
  • the invention concerns a method for the bronchodilatory treatment of all forms of asthma and chronic obstructive pulmonary disease (COPD) which comprises administration to a patient in need thereof of a therapeutically effective amount of the composition of the invention.
  • COPD chronic obstructive pulmonary disease
  • the invention comprises a process for preparation of the composition of the invention, in the form of tablets, which comprises:
  • phase (b) compressing is performed to obtain a tablet hardness of between 1 and 3 kg/cm .
  • phase (d) in phase (d) a lubricating agent and/or a filling agent are mixed.
  • composition of the present invention can also be formulated in the form of coated pellets.
  • compositions of the invention have undergone various tests to assess their dissolution profile and stability, as well as their in vivo bioavailability.
  • composition of the invention in particular the preferred composition in the form of a tablet, as defined above, is stable and has an optimal dissolution profile for maintaining the haematic concentration of doxofylline effective for 24 hours.
  • compositions of the invention are therefore suitable for administration once a day only and, surprisingly, at a dosage even approximately 35% lower than the daily dosage of the conventional formulations.
  • doxofylline 650.00 mg cellulose esters and/or ethers 50.00 mg microcrystalline cellulose 30.00 mg magnesium stearate 5.00 mg
  • a modified release composition in tablet form is prepared which contains, for each tablet: doxofylline 650.00 mg cellulose esters and/or ethers 125.00 mg microcrystalline cellulose 100.00 mg magnesium stearate 7.00 mg talc 18.00 mg EXAMPLE 3
  • a modified release composition in tablet form is prepared which contains, for each tablet: doxofylline 600.00 mg cellulose esters and/or ethers 50.00 mg microcrystalline cellulose 30.00 mg magnesium stearate 5.00 mg

Abstract

The invention concerns a modified release doxofylline-based pharmaceutical composition, for administration once a day only, comprising a polymer chosen from a pharmaceutically acceptabel cellulose derivative and a pharmaceutically acceptable methacrylate derivative.

Description

"MODIFIED RELEASE COMPOSITION COMPRISING DOXOFYLLINE"
************
FIELD OF THE INVENTION
The present invention concerns a new doxofylline comprising pharmaceutical composition, in particular a modified release formulation, for administration once a day only.
TECHNICAL BACKGROUND
Doxofylline (7-(l,3-dioxalan-2-ylmethyl)-theophylline) is a drug derived from theophylline which is used in therapy as a bronchodilator, with anti-inflammatory action, in reversible airway obstruction. It is commonly administered in doses ranging from 800 to 1200 mg per day, orally, according to a dosage which provides for the intake of two to three dosage units per day in order to maintain therapeutically effective haematic levels. The doxofylline tablets commercially available generally contain 400 mg of active ingredient and release almost all the drug within one hour from intake. The half-life of the drug is around 6-7 hours and for this reason several administrations are required during the 24-hour period. Obviously a drop in haematic concentration of the drug in an asthmatic patient or patient suffering from COPD (chronic obstructive pulmonary disease) can result in serious consequences, in which case the patient must have recourse to emergency drugs, such as salbutamol for example.
Pharmaceutical techniques for obtaining the modified release of drugs have been known for some time, but no modified release formulation of doxofylline is known. In fact the present inventors have observed that there are significant difficulties in the production of a doxofylline formula that can be administered only once a day and in particular have encountered problems correlated with bioequivalence. Various attempts to formulate doxofylline in modified release systems, with different known polymers, have not provided the desired results, i.e. a composition that can be administered once a day, bioequivalent to the plasmatic concentration obtained with the traditional compositions currently on sale, hi fact currently, dosage units containing 400 mg of active ingredient are currently administered two/three times a day for an average of approximately 1000 mg of active ingredient, a dosage considered necessary to maintain the therapeutic haematic levels of doxofylline. OBJECTS OF THE INVENTION
One object of the present invention is to provide a modified release composition of doxofylline which is bioequivalent to the therapy currently used and which eliminates the need to take several doses per day, thus improving patient compliance. A further object of the present invention is to provide a composition of doxofylline which eliminates the initial haematic peak and the first-pass effect occurring in the conventional compositions. A further object of the present invention is to provide a doxofylline composition which maintains the effective concentration of the drug in the blood sufficient to exert the bronchodilatory and anti-inflammatory effect over the 24-hour period, thus reducing the risk of bronchospasm and serious consequences for the patient. Another object of the present invention is to provide a modified release doxofylline composition which avoids the need for recourse to emergency drugs, such as salbutamol, to overcome acute asthmatic attacks and bronchospasms.
The above objects have been unexpectedly achieved with the composition of the invention which moreover comprises a surprisingly lower dose of active ingredient than the daily dose commonly used. DESCRIPTION OF THE INVENTION According to one of its embodiments, the invention concerns a modified release pharmaceutical composition which comprises as active ingredient doxofylline, and a polymer selected from a pharmaceutically acceptable cellulose derivative, a pharmaceutically acceptable methacrylate derivative, their mixtures, and pharmaceutically acceptable salts thereof. Doxofylline (or doxophylline) (7-(l,3-dioxalan-2-ylmethyl)-theophylline) has the following structural formula
Figure imgf000004_0001
and is here also called "active ingredient" or "API" (Active Pharmaceutical Ingredient).
According to the present invention, "modified release pharmaceutical composition" indicates a pharmaceutical composition that retains the active ingredient for a longer period of time than the conventional compositions and releases it slowly in order to maintain at length the plasmatic concentrations of the drug sufficient to exert the desired therapeutic effect. Said formulation is here also called "BET" (Bioavailability Enhancing Technology) formulation. The term "polymer" indicates, according to the present invention, a pharmaceutically acceptable release modulator polymer or copolymer, suitable for prolonging the release time of the active ingredient from the composition. Said polymer will be indicated below also simply as "release modulator polymer". The expression "pharmaceutically acceptable cellulose derivative" indicates a derivative suitable for prolonging the release time of the drug from the composition, such as pharmaceutically acceptable cellulose esters and ethers, like methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, their mixtures and their salts.
The expression "pharmaceutically acceptable methacrylate derivative" indicates a derivative suitable for prolonging the release time of the drug from the composition, for example the copolymer methacrylic acid/methyl methacrylate, the copolymer methacrylic acid/ethyl methacrylate, their mixtures and their salts. A preferred release modulator polymer according to the invention is a pharmaceutically acceptable cellulose derivative, advantageously selected from methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose and their mixtures.
The composition of the invention is preferably a composition in the form of a dosage unit suitable for oral administration once a day, advantageously in the form of a tablet.
The composition of the invention preferably also comprises excipients useful for the processing thereof, for example lubricating agents, such as magnesium stearate, filling agents, such as lactose, talc, microcrystalline cellulose, agents aiding compression and, if necessary or desired, other excipients such as aromatizers, sweeteners, preservatives, etc., well known to a person skilled in the art.
The composition of the invention preferably comprises a quantity of active ingredient between 600 and 800 mg, preferably between 625 and 700 mg, advantageously around 650 mg. It is understood that said dose can vary according to the age, weight and state of health of the patient. It has been unexpectedly observed, however, during the bioequivalence assays, that it is not necessary to administer a quantity of active ingredient equal to the daily dosage of the conventional compositions currently on the market (400 mg, two/three times a day, on average 1,000 mg per day) but that thanks to the composition of the invention, it is possible to obtain a bioequivalent plasmatic concentration even at a very low dosage, for example with 650 mg of active ingredient.
This unexpected fact is particularly important as it allows to obtain the same therapeutic effect with a lower dose, even approximately 35% lower, of active ingredient and therefore results in a reduction in side effects and therefore an important benefit for the patient, and at the same time a reduction in industrial costs due to the production and processing of the active ingredient. According to a particularly preferred aspect, the invention concerns a modified release composition which comprises as active ingredient approximately 650 mg of doxofylline and a release modulator polymer as defined above, advantageously in combination with a filling agent and/or a lubricant. The release modulator polymers are used alone or mixed together, in quantities between 30 mg and 200 mg per tablet, preferably between 40 mg and 130 mg, for example, 50, 100 or 125 mg, per dosage unit.
The composition of the invention has proved to be particularly suitable for modified release of the active ingredient and with one single oral administration allows an effective haematic concentration of doxofylline to be maintained for 24 hours, while time avoiding the excessive haematic peak which characterises the conventional compositions currently on sale. The preferred composition of the invention advantageously also comprises a lubricant, for example magnesium stearate, for example in quantities between 1 and 15 mg, preferably between 3 and 10 mg, for example approximately 5 mg, per dosage unit.
The preferred composition of the invention advantageously also comprises one or more filling agents, such as talc, lactose or microcrystalline cellulose, for example in total quantities of between 10 and 200 mg, for example between 20 and 150 mg, advantageously 30, 50, 70 or 100 mg, per dosage unit.
The composition of the invention is preferably in the form of a tablet and can be prepared by mixing the active ingredient, the release modulator polymer (or the mixture of polymers) and any other components and compressing them to an appropriate hardness, according to the methods known in the art.
According to another of its aspects, the invention concerns use of the composition of the invention for the preparation of a bronchodilatory medication with anti- inflammatory action for the treatment of all forms of asthma and chronic obstructive pulmonary disease (COPD). According to a further aspect, the invention concerns use of the composition of the invention for the preparation of a medication for oral adrninistration once a day only. According to another of its aspects, the invention concerns a method for the bronchodilatory treatment of all forms of asthma and chronic obstructive pulmonary disease (COPD) which comprises administration to a patient in need thereof of a therapeutically effective amount of the composition of the invention.
According to another of its aspects, the invention comprises a process for preparation of the composition of the invention, in the form of tablets, which comprises:
(a) mixing the doxofylline with the release modulator polymer and optionally a filling agent;
(b) pre-compressing the mixture (a); (c) grinding the mixture compressed in (b);
(d) optionally mixing the mixture ground in (c) with the other desired excipients;
(e) compressing the mixture (d).
According to another preferred aspect, in phase (b) compressing is performed to obtain a tablet hardness of between 1 and 3 kg/cm .
According to a further preferred aspect, in phase (d) a lubricating agent and/or a filling agent are mixed.
The examples given in the experimental section of the present description provide embodiments illustrating the composition of the present invention. The composition of the invention can also be formulated in the form of coated pellets.
The compositions of the invention have undergone various tests to assess their dissolution profile and stability, as well as their in vivo bioavailability.
The tests conducted enabled us to conclude that the composition of the invention, in particular the preferred composition in the form of a tablet, as defined above, is stable and has an optimal dissolution profile for maintaining the haematic concentration of doxofylline effective for 24 hours.
Furthermore, the bioavailability tests conducted on the preferred composition in the form of a tablet, as defined above, provided excellent results and, when compared with the conventional compositions (for example 400 mg two/three times a day) of doxofylline, they showed an unexpected improvement in bioavailability. The compositions of the invention are therefore suitable for administration once a day only and, surprisingly, at a dosage even approximately 35% lower than the daily dosage of the conventional formulations. EXPERIMENTAL SECTION EXAMPLE 1 A modified release composition in tablet form is prepared which contains, for each tablet: doxofylline 650.00 mg cellulose esters and/or ethers 50.00 mg microcrystalline cellulose 30.00 mg magnesium stearate 5.00 mg
EXAMPLE 2
A modified release composition in tablet form is prepared which contains, for each tablet: doxofylline 650.00 mg cellulose esters and/or ethers 125.00 mg microcrystalline cellulose 100.00 mg magnesium stearate 7.00 mg talc 18.00 mg EXAMPLE 3
A modified release composition in tablet form is prepared which contains, for each tablet: doxofylline 600.00 mg cellulose esters and/or ethers 50.00 mg microcrystalline cellulose 30.00 mg magnesium stearate 5.00 mg

Claims

1. A modified release pharmaceutical composition which comprises as the active ingredient doxofylline, in combination with a polymer chosen from a pharmaceutically acceptable cellulose derivative, a pharmaceutically acceptable methacrylate derivative, their mixtures, and pharmaceutically acceptable salts thereof.
2. The composition as claimed in claim 1, characterised in that the polymer is selected from the pharmaceutically acceptable cellulose esters and ethers.
3. The composition as claimed hi claim 2, characterised in that the polymer is selected from methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, their mixtures and salts.
4. The composition as claimed in claim 1, characterised hi that the polymer is the copolymer methacrylic acid/methyl methacrylate, the copolymer methacrylic acid/ethyl methacrylate, their mixtures and salts.
5. The composition as claimed in any one of the preceding claims, characterised in that it is in the form of an oral tablet.
6. The composition as claimed in any one of the preceding claims, characterised in that it further comprises one or more components selected from lubricating agents, filling agents, agents aiding compression and their combinations.
7. The composition as claimed hi any one of the preceding claims, characterised in that it is in dosage units, hi the form of a tablet, and that it comprises a quantity of active ingredient between 600 and 800 mg.
8. The composition as claimed in claim 7, characterised in that it comprises 650 mg of active ingredient.
9. The composition as claimed in claim 8, characterised in that it comprises 650 mg of doxofylline and between 40 and 130 mg of polymer of the claim 2 or 3.
10. The composition as claimed in claim 9, characterised in that it further comprises a lubricant and/or a filling agent.
11. The composition as claimed hi claim 10, characterised in that it comprises from 1 to 15 mg of lubricant.
12. The composition as claimed in claims 10 or 11, characterised in that it comprises from 10 to 200 mg of filling agent.
13. The composition as claimed in any one of the claims from 7 to 12, which comprises 650.00 mg of doxofylline, 50.00 mg of a cellulose ester and/or ether,
30.00 mg of microcrystalline cellulose and 5.00 mg of magnesium stearate.
14. The composition as claimed in any one of the claims from 7 to 12, which comprises 650.00 mg of doxofylline, 125.00 mg of a cellulose ester and/or ether, 100.00 mg of microcrystalline cellulose, 18.00 mg of talc and 7.00 mg of magnesium stearate.
15. A process for preparation of the composition according to any one of the preceding claims, in oral tablet form, which comprises:
(a) mixing the doxofylline with the polymer and optionally a filling agent; (b) pre-compressing the mixture (a);
(c) grinding the mixture compressed in (b);
(d) optionally mixing the mixture ground in (c) with the other excipients;
(e) compressing the mixture (d).
16. A use of a composition as claimed in any one of the claims from 1 to 14, for the preparation of a bronchodilatory medicament and for the treatment of all forms of asthma and chronic obstructive pulmonary disease (COPD).
17. The use as claimed in claim 16, for the preparation of a medication for administration once a day only.
18. The composition as claimed in any one of the claims from 1 to 14, for use as a bronchodilator and in the treatment of all forms of asthma and chronic obstructive pulmonary disease (COPD).
PCT/IB2008/000554 2008-03-10 2008-03-10 Modified release composition comprising doxofylline WO2009112874A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2008010233A MX2008010233A (en) 2008-03-10 2008-03-10 Modified release composition comprising doxofylline.
PCT/IB2008/000554 WO2009112874A1 (en) 2008-03-10 2008-03-10 Modified release composition comprising doxofylline
KR1020087020018A KR101697773B1 (en) 2008-03-10 2008-03-10 Modified release composition comprising doxofylline
IT000798A ITMI20080798A1 (en) 2008-03-10 2008-04-30 MODEL RELEASED COMPOSITION BASED ON DOXOFILLINA
EP09721101A EP2262485A1 (en) 2008-03-10 2009-03-06 Modified release composition comprising doxofylline
PCT/EP2009/052675 WO2009112436A1 (en) 2008-03-10 2009-03-06 Modified release composition comprising doxofylline
AU2009224801A AU2009224801B2 (en) 2008-03-10 2009-03-06 Modified release composition comprising doxofylline
BRPI0906158A BRPI0906158B8 (en) 2008-03-10 2009-03-06 modified release pharmaceutical composition comprising doxophyllin and process for preparing the composition
MX2010009917A MX2010009917A (en) 2008-03-10 2009-03-06 Modified release composition comprising doxofylline.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/000554 WO2009112874A1 (en) 2008-03-10 2008-03-10 Modified release composition comprising doxofylline

Publications (1)

Publication Number Publication Date
WO2009112874A1 true WO2009112874A1 (en) 2009-09-17

Family

ID=40084194

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2008/000554 WO2009112874A1 (en) 2008-03-10 2008-03-10 Modified release composition comprising doxofylline
PCT/EP2009/052675 WO2009112436A1 (en) 2008-03-10 2009-03-06 Modified release composition comprising doxofylline

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/052675 WO2009112436A1 (en) 2008-03-10 2009-03-06 Modified release composition comprising doxofylline

Country Status (7)

Country Link
EP (1) EP2262485A1 (en)
KR (1) KR101697773B1 (en)
AU (1) AU2009224801B2 (en)
BR (1) BRPI0906158B8 (en)
IT (1) ITMI20080798A1 (en)
MX (2) MX2008010233A (en)
WO (2) WO2009112874A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524503A (en) * 2013-10-29 2014-01-22 天津梅花医药有限公司 Doxofylline hemihydrate

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150063040A (en) * 2012-09-26 2015-06-08 유로드러그 레버러토리즈 비. 브이. Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations
CN110898019A (en) * 2019-12-19 2020-03-24 上海宣泰海门药业有限公司 Doxofylline tablet and preparation method thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983000284A1 (en) * 1981-07-15 1983-02-03 Key Pharma Sustained release theophylline
EP0231826A2 (en) * 1986-02-04 1987-08-12 Farvalsa AG Theophylline sustained release tablet
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
EP0797987A1 (en) * 1994-12-19 1997-10-01 Daiichi Pharmaceutical Co., Ltd. Sustained-release granular preparation and process for producing the same
WO2003097050A2 (en) * 2002-05-16 2003-11-27 Pharmacia Corporation A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
US20060194842A1 (en) * 2005-02-22 2006-08-31 Chikara Uchida Oxyindole derivatives
EP1698375A1 (en) * 2003-12-25 2006-09-06 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
WO2008033351A2 (en) * 2006-09-11 2008-03-20 Theraquest Biosciences, Inc. Multimodal abuse resistant and extended release formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100536849C (en) * 2006-05-10 2009-09-09 鲁南制药集团股份有限公司 Medicine composition containing theocin-like medicines and vitamin K
CN101028254B (en) * 2007-04-05 2010-05-19 合肥合源医药科技股份有限公司 Sustaining agent of Duosuo theosine and its preparation

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983000284A1 (en) * 1981-07-15 1983-02-03 Key Pharma Sustained release theophylline
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
EP0231826A2 (en) * 1986-02-04 1987-08-12 Farvalsa AG Theophylline sustained release tablet
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
EP0797987A1 (en) * 1994-12-19 1997-10-01 Daiichi Pharmaceutical Co., Ltd. Sustained-release granular preparation and process for producing the same
WO2003097050A2 (en) * 2002-05-16 2003-11-27 Pharmacia Corporation A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
EP1698375A1 (en) * 2003-12-25 2006-09-06 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
US20060194842A1 (en) * 2005-02-22 2006-08-31 Chikara Uchida Oxyindole derivatives
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2008033351A2 (en) * 2006-09-11 2008-03-20 Theraquest Biosciences, Inc. Multimodal abuse resistant and extended release formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CEBALLOS ET AL: "Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets", FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 60, no. 11-12, 1 November 2005 (2005-11-01), pages 913 - 918, XP005151562, ISSN: 0014-827X *
NARISAWA S ET AL: "Drug release behavior in gastrointestinal tract of beagle dogs from multiple unit type rate-controlled or time-controlled release preparations coated with insoluble polymer-based film", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 33, no. 2, 1 February 1995 (1995-02-01), pages 253 - 260, XP004037628, ISSN: 0168-3659 *
SIEPMANN ET AL: "Polymer blends for controlled release coatings", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 125, no. 1, 13 October 2007 (2007-10-13), pages 1 - 15, XP022375058, ISSN: 0168-3659 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524503A (en) * 2013-10-29 2014-01-22 天津梅花医药有限公司 Doxofylline hemihydrate

Also Published As

Publication number Publication date
MX2008010233A (en) 2009-11-10
KR20100124860A (en) 2010-11-30
BRPI0906158B8 (en) 2021-05-25
BRPI0906158B1 (en) 2021-01-05
WO2009112436A1 (en) 2009-09-17
AU2009224801A1 (en) 2009-09-17
KR101697773B1 (en) 2017-01-18
AU2009224801B2 (en) 2014-06-05
EP2262485A1 (en) 2010-12-22
MX2010009917A (en) 2010-12-21
BRPI0906158A2 (en) 2017-07-18
ITMI20080798A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
JP2018514534A5 (en)
JP2001517626A (en) Compositions and methods for treating respiratory disorders
WO2009034540A1 (en) Pharmaceutical composition of sevelamer
WO2009112874A1 (en) Modified release composition comprising doxofylline
EP2802311B1 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
RU2449778C1 (en) Diuretic composition with delayed release
ZA200504425B (en) Pharmaceutical formulations comprins beta-2 andrenoreceptor antagonists and xanthines
WO2012104641A2 (en) Pharmaceutical formulation
CN113908153B (en) Buvaracetam pharmaceutical composition, preparation method and application thereof
JP2005187328A (en) Antipyretic and analgesic composition comprising ibuprofen and drug for common cold
JP6018891B2 (en) Antipyretic analgesic composition
KR20130086771A (en) Composition for oral fast dissolving film and pharmaceutical for oral fast dissolving film containing pde5 inhibitor drugs
JP2011046666A (en) Medicinal composition
JP2005289906A (en) Medicinal composition
JPH08208483A (en) Mequitazine-containing pharmaceutical preparation
JP3935539B2 (en) Pharmaceutical composition containing ketotifen fumarate
US20190209551A1 (en) Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
JP2005289902A (en) Medicinal composition
JP2021088591A (en) Pharmaceutical formulation comprising one or more fumaric acid esters in erosion matrix
TW202300138A (en) Lacosamide pharmaceutical composition, preparation method and application thereof
CN111643672A (en) Liquid composition comprising choline salicylic acid and phenylephrine, method of making and use thereof
JP2001089375A (en) Composition for common cold
WO2007113371A1 (en) Pharmaceutical composition and preparation method thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 4191/CHENP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/010233

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020087020018

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08719262

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08719262

Country of ref document: EP

Kind code of ref document: A1